376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

Shanu Modi, William Jacot, Hiroji Iwata, Y.H. Park, M.J. Vidal Losada, Wei Li, Junji Tsurutani, Khalil Zaman, Naoto T. Ueno, Aleix Prat, Konstantinos Papazisis, H. S. Rugo, Nadia Harbeck, S-A. Im, Michelino De Laurentiis, Cecilia Orbegoso, Lotus Yung, F-C. Cheng, Yun Cheng, David Cameron